CL2020000973A1 - Composiciones y procedimientos para el tratamiento de linfoma difuso de celulas b grandes. - Google Patents
Composiciones y procedimientos para el tratamiento de linfoma difuso de celulas b grandes.Info
- Publication number
- CL2020000973A1 CL2020000973A1 CL2020000973A CL2020000973A CL2020000973A1 CL 2020000973 A1 CL2020000973 A1 CL 2020000973A1 CL 2020000973 A CL2020000973 A CL 2020000973A CL 2020000973 A CL2020000973 A CL 2020000973A CL 2020000973 A1 CL2020000973 A1 CL 2020000973A1
- Authority
- CL
- Chile
- Prior art keywords
- procedures
- compositions
- treatment
- cell lymphoma
- diffuse large
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762571870P | 2017-10-13 | 2017-10-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020000973A1 true CL2020000973A1 (es) | 2020-12-28 |
Family
ID=64110107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020000973A CL2020000973A1 (es) | 2017-10-13 | 2020-04-09 | Composiciones y procedimientos para el tratamiento de linfoma difuso de celulas b grandes. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20200262919A1 (https=) |
| EP (1) | EP3694520A1 (https=) |
| JP (2) | JP2020536923A (https=) |
| KR (1) | KR20200068655A (https=) |
| CN (1) | CN111212646A (https=) |
| AU (1) | AU2018347457A1 (https=) |
| BR (1) | BR112020007203A2 (https=) |
| CA (1) | CA3075291A1 (https=) |
| CL (1) | CL2020000973A1 (https=) |
| EA (1) | EA202090565A1 (https=) |
| IL (1) | IL273805A (https=) |
| MX (2) | MX2020003395A (https=) |
| SG (1) | SG11202002374RA (https=) |
| TW (1) | TW201922283A (https=) |
| WO (1) | WO2019075366A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2021183861A1 (en) * | 2020-03-12 | 2021-09-16 | Amgen Inc. | Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor |
| US20230331844A1 (en) * | 2020-10-12 | 2023-10-19 | Greffex, Inc. | Antibody constructs to target t cell responses to sars-cov protein expressing cells, their design and uses |
| JP2026502330A (ja) * | 2022-11-01 | 2026-01-22 | テネオツー・インコーポレイテッド | 非ホジキンリンパ腫を治療する方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| CZ302070B6 (cs) | 1998-04-21 | 2010-09-29 | Micromet Ag | Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto |
| CA2522586C (en) | 2003-05-31 | 2017-02-21 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| WO2008119565A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific binding domain |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2016019969A1 (en) * | 2014-08-08 | 2016-02-11 | Ludwig-Maximilians-Universität München | Subcutaneously administered bispecific antibodies for use in the treatment of cancer |
| US10751412B2 (en) | 2015-05-29 | 2020-08-25 | Merck Sharp & Dohme Corp. | Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer |
| EP3316888A1 (en) * | 2015-07-02 | 2018-05-09 | Celgene Corporation | Combination therapy for treatment of hematological cancers and solid tumors |
-
2018
- 2018-10-12 EA EA202090565A patent/EA202090565A1/ru unknown
- 2018-10-12 BR BR112020007203-6A patent/BR112020007203A2/pt unknown
- 2018-10-12 MX MX2020003395A patent/MX2020003395A/es unknown
- 2018-10-12 EP EP18797306.0A patent/EP3694520A1/en not_active Withdrawn
- 2018-10-12 US US16/648,568 patent/US20200262919A1/en not_active Abandoned
- 2018-10-12 JP JP2020520587A patent/JP2020536923A/ja active Pending
- 2018-10-12 WO PCT/US2018/055667 patent/WO2019075366A1/en not_active Ceased
- 2018-10-12 AU AU2018347457A patent/AU2018347457A1/en not_active Abandoned
- 2018-10-12 SG SG11202002374RA patent/SG11202002374RA/en unknown
- 2018-10-12 CA CA3075291A patent/CA3075291A1/en active Pending
- 2018-10-12 KR KR1020207009219A patent/KR20200068655A/ko not_active Ceased
- 2018-10-12 CN CN201880066675.2A patent/CN111212646A/zh active Pending
- 2018-10-15 TW TW107136236A patent/TW201922283A/zh unknown
-
2020
- 2020-04-05 IL IL273805A patent/IL273805A/en unknown
- 2020-04-09 CL CL2020000973A patent/CL2020000973A1/es unknown
- 2020-07-13 MX MX2024001888A patent/MX2024001888A/es unknown
-
2023
- 2023-09-27 JP JP2023164647A patent/JP2024001071A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3694520A1 (en) | 2020-08-19 |
| JP2024001071A (ja) | 2024-01-09 |
| KR20200068655A (ko) | 2020-06-15 |
| MX2024001888A (es) | 2024-02-29 |
| BR112020007203A2 (pt) | 2020-10-20 |
| MX2020003395A (es) | 2020-08-03 |
| WO2019075366A1 (en) | 2019-04-18 |
| US20200262919A1 (en) | 2020-08-20 |
| EA202090565A1 (ru) | 2020-10-13 |
| IL273805A (en) | 2020-05-31 |
| CN111212646A (zh) | 2020-05-29 |
| AU2018347457A1 (en) | 2020-04-09 |
| JP2020536923A (ja) | 2020-12-17 |
| SG11202002374RA (en) | 2020-04-29 |
| TW201922283A (zh) | 2019-06-16 |
| CA3075291A1 (en) | 2019-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3661514T (lt) | Mavakamtenas, skirtas naudoti gydant hipertrofinę kardiomiopatiją | |
| IL259441A (en) | Materials and methods for treatment of titin-based myopathies and other titinopaties | |
| IL256056A (en) | Ezh2 inhibitors for treating lymphoma | |
| PT3407888T (pt) | Compostos de piridopirroloquinoxalina, suas composições e utilizações | |
| PL3658140T3 (pl) | Połączenia aprocitentanu z dodatkowymi składnikami czynnymi do leczenia opornego nadciśnienia | |
| HUE053191T2 (hu) | 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére | |
| LT3200815T (lt) | Būdai ir kompozicijos, skirti vėžio gydymui | |
| PL3493812T3 (pl) | Połączenia imetelstatu i wenetoklaksu do leczenia ostrej białaczki szpikowej | |
| EP3617287A4 (en) | THICKENING AGENT, COMPOSITION AND SHEET | |
| GB2588261B (en) | Apparatus, use of the apparatus and arrangement | |
| HUE043259T2 (hu) | Sarzskeverõ üzemeltetési eljárása, valamint sarzskeverõ az eljárás foganatosítására | |
| ZA201903928B (en) | Compositions comprising methylphenidate-prodrugs, processes of making and using the same | |
| EP3654982A4 (en) | 1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES | |
| CL2018001502A1 (es) | Procedimiento para el tratamiento de efluente acuoso. | |
| CL2020000973A1 (es) | Composiciones y procedimientos para el tratamiento de linfoma difuso de celulas b grandes. | |
| EP3555127C0 (en) | AGENTS, USES AND METHODS | |
| EP3517581A4 (en) | COATING COMPOSITION, COATING FILM, AND COATING PROCESS | |
| DK3302478T3 (da) | Pac-1 kombinations behandling | |
| EP3536718A4 (en) | FLUORINATED POLYMER AND COMPOSITION OF SURFACE TREATMENT AGENT | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
| LT3273957T (lt) | Biotinas, skirtas demielinizuojančių neuropatijų gydymui | |
| MX2015009277A (es) | Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina. | |
| PL3373922T3 (pl) | Kompozycje i sposoby do stosowania do leczenia homocystynurii | |
| LT3229790T (lt) | Kompozicijos, apimančios vidutinės grandinės trigliceridus, skirtos panaudoti epilepsijos gydyme | |
| IT201700104446A1 (it) | Compositions, uses and methods for treatment of infertility and subfertility |